PERF Monthly Newsletter – June 2015

monthly newsletter header

JUNE
2015

Here is a roundup of the articles, news & updates that we've published on the PERF blog site during the past month. Click on the "Read More" link at the bottom of each excerpt to read the full article.

dividing line

[column-group][column]

Leonard Nimoy Still A Force – for COPD Awareness and Treatment

Leonard Nimoy still lives on as a force for the improvement of outcomes for COPD patients; his daughter Julie Nimoy is developing a documentary to help COPD sufferers, in honor of her father who also suffered from the disease. PERF is proud to announce that she has asked PERF President Richard Casaburi, PhD, MD, a lead researcher at the Los Angeles Biomedical Research Institute (LA BioMed), to serve as medical adviser for the film.

…Read More

[/column][column]

New Clinical Trial at LA BioMed/Harbor-UCLA and USC Offers Hope for Emphysema Patients

LOS ANGELES, Calif. – June 4, 2015 – A clinical trial for patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease (COPD), recently commenced at two Los Angeles medical centers to study a new, investigational treatment that may help them breathe easier without surgery.

…Read More

[/column][/column-group]

[column-group][column]

Is It Worth Moving to a Different Altitude to Relieve the Symptoms of COPD?

If you have COPD and live at a high altitude, such as in Denver, should you consider pulling up roots and moving somewhere closer to sea level? Will such a move help you avoid, or at least postpone, the need to use oxygen?

The simple answer is yes. The real-life answer, however, may be different.

…Read More

[/column][column]

New Drug Approved by FDA for Treatment of COPD – Stiolto Respimat

According to a recent article in Medscape, a new drug has cleared the final hurdles for FDA approval and is now available for treatment of patients with COPD: Stiolto Respimat (Boehringer Ingelheim). This once-daily oral inhalation spray combines tiotropium and olodaterol.

…Read More

[/column][/column-group]

[feather_share]
No Comments

Sorry, the comment form is closed at this time.